Nanobiotix (NASDAQ:NBTX) Stock Price Up 5% – Should You Buy?

Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) shares rose 5% on Thursday . The company traded as high as $23.68 and last traded at $23.6760. Approximately 33,646 shares changed hands during trading, a decline of 7% from the average daily volume of 36,145 shares. The stock had previously closed at $22.54.

Analyst Ratings Changes

A number of equities analysts have commented on NBTX shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Nanobiotix in a report on Wednesday, October 8th. HC Wainwright reaffirmed a “buy” rating on shares of Nanobiotix in a research report on Tuesday, November 4th. Wall Street Zen upgraded Nanobiotix to a “hold” rating in a research note on Saturday, October 25th. Finally, Leerink Partners restated an “outperform” rating on shares of Nanobiotix in a research note on Tuesday, November 25th. Three equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $11.00.

Nanobiotix Stock Down 2.3%

The stock has a 50 day moving average of $21.79 and a 200 day moving average of $12.63.

Institutional Investors Weigh In On Nanobiotix

A hedge fund recently bought a new position in Nanobiotix stock. Optiver Holding B.V. bought a new position in Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 5,356 shares of the company’s stock, valued at approximately $101,000. Hedge funds and other institutional investors own 38.81% of the company’s stock.

About Nanobiotix

Nanobiotix SA, a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer.